▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2966 by analyst upside · 2026-11-14
LIVN
LivaNova PLC
Healthcare · Market Cap $5B · P/E 25.9x
ANALYST PRICE TARGET
+15.1%
implied upside to consensus target
Current Price $91.32
Consensus Target $105.09
Bull Target $120.0
Bear Target $75.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
1
Sell
1
52-Week Low $52.37
52-Week High $99.38
YTD Return +50.6%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) 25.9x
Forward P/E 19.3x
EPS (TTM) $3.53
PEG Ratio 0.93
Dividend Yield N/A
Revenue (TTM) $1.5B
Profit Margin 13.0%
52-WEEK RANGE
52-Week Low $52.37
52-Week High $99.38
Current Price $91.32
Bear Target $75.0
Bull Target $120.0
● Now $91.32 ● Target $105.09
TRADING DATA
Avg Volume 665K
YTD Return +50.6%
Analyst Count 11
Consensus Buy
Upside to Target +15.1%
Last Updated 2026-11-14

ANALYST SUMMARY

LivaNova PLC (LIVN) is currently trading at $91.32 with a Wall Street consensus price target of $105.09, implying potential upside of 15.1% over the next 12 months. 11 analysts currently cover LIVN, with a consensus rating of Buy - 82% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $75.0.

LIVN operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 50.6% year-to-date and is currently trading near the upper end of its 52-week range of $52.37 – $99.38.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SHC +29.1%
Sotera Health Company
$5B · P/E 27.2x · Buy
OPCH -5.1%
Option Care Health, Inc.
$5B · P/E 22.9x · Hold
MMSI +23.5%
Merit Medical Systems, Inc.
$5B · P/E 32.4x · Buy
DOCS -5.5%
Doximity, Inc.
$6B · P/E 46.3x · Buy
PACS +29.3%
PACS Group, Inc.
$8B · P/E 27.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for LIVN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Baird - Reiterated
Outperform → Outperform 2026-11-05 Building track record
Needham - Reiterated
Buy → Buy 2026-11-04 20% win rate (5 calls)
Barclays ● Initiated
Overweight 2026-10-07 Building track record
Piper Sandler reit
Overweight → Overweight 2026-09-02 14% win rate (7 calls)
Needham - Reiterated
Buy → Buy 2026-08-05 20% win rate (5 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-07-15 Building track record
Freedom Capital Markets ● Initiated
Hold 2026-07-01 Building track record
Keybanc - Reiterated
Overweight → Overweight 2026-06-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
19/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →